

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A human antibody that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet ~~agglutination~~ independently, or an active-fragment thereof.
2. (Currently Amended) A human antibody that specifically binds to human platelet membrane glycoprotein VI and suppresses collagen-mediated human platelet ~~agglutination~~ by in vivo administration, or an active-fragment thereof.
3. (Currently Amended) A human antibody that specifically binds to human GPVI and has any one or more functions of the following functions: specifically inhibiting a binding of GPVI on the platelet to collagen; disappearing a ~~functionable~~ functional GPVI on the platelet; or decreasing or deleting a collagen-mediated ~~agglutinability~~ of the human platelet by preliminarily contacting with the human platelet, or an active-fragment thereof.
4. (Currently Amended) A human antibody that specifically binds to human platelet membrane glycoprotein VI, suppresses a collagen-mediated ~~agglutinability~~ of the human platelet and does not induce a human platelet ~~agglutination~~ independently, or an active-fragment thereof.
5. (Original) An antibody or an active fragment thereof, wherein VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 98, SEQ ID NO: 99 and SEQ ID NO: 100, respectively; or VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
6. - 7. (Deleted)
8. (Currently Amended) A pharmaceutical composition that comprises the antibody of one of claims 1 through 4 or an active fragment thereof as an active ingredient.

9. (Deleted)

10. (New) An antibody or an active fragment thereof, wherein VH CDR1, VH CDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 has the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 101, SEQ ID NO: 102 and SEQ ID NO: 103, respectively; SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 142, SEQ ID NO: 104 and SEQ ID NO: 105, respectively; SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 106, SEQ ID NO: 107 and SEQ ID NO: 108, respectively; SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 109, SEQ ID NO: 110 and SEQ ID NO: 111, respectively; SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 112, SEQ ID NO: 113 and SEQ ID NO: 114, respectively; SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117, respectively; SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 118, SEQ ID NO: 119 and SEQ ID NO: 120, respectively; SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 121, SEQ ID NO: 122 and SEQ ID NO: 123, respectively; SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 124, SEQ ID NO: 125 and SEQ ID NO: 126, respectively; SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129, respectively; SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 130, SEQ ID NO: 131 and SEQ ID NO: 132, respectively; SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 134 and SEQ ID NO: 135, respectively; SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 136, SEQ ID NO: 137 and SEQ ID NO: 138, respectively; or SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 139, SEQ ID NO: 140 and SEQ ID NO: 141, respectively.

11. (New) An antibody or an active fragment thereof, which comprises SEQ ID NO: 15 within the H-chain variable region and/or SEQ ID NO: 16 within the L-chain variable region, or which comprises SEQ ID NO: 143 within the H-chain variable region and/or SEQ ID NO: 144 within the L-chain variable region.